| Ytd | -16.38% | |
| 1y | -63.57% |
| Open | 5.83 | Prev Close | 5.77 | Low | 5.71 | High | 5.97 | Mkt Cap | 65.08M |
| Vol | 29.00 | Avg Vol | 351.70K | EPS | -4.78 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 5.74 | 200-d Avg | 6.62 | 1yr Est | 0.00 |
IMA News
WASHINGTON--(BUSINESS WIRE)-- #Education--The Independent Medical Alliance (IMA) today announced the
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Compan
ImageneBio (NASDAQ:IMA) reported quarterly losses of $(0.95) per share which missed the analyst cons
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Compan
ImageneBio is a clinical-stage biopharmaceutical company focused on developing therapeutics for immu
ImageneBio shares rise after a $30 million private placement to advance IMG-007 development for atop
IMA: 41% | ImageneBio Raises $30M Via Private Institutional Placement To Fund Hair Loss And Skin Dis
ImageneBio, Inc. (NASDAQ:IMA)("Imagene" or the "Company") today announced it has ent
SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA)(“Imagene” or the “Compa
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Comp
ImageneBio (NASDAQ:IMA) reported quarterly losses of $(6.73) per share which missed the analyst cons
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Comp
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Compa
BML Capital Management LLC purchased a new position in ImageneBio, Inc. (NASDAQ: IMA) in the undefin
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, includi
Wedbush analyst Martin Fan assumes ImageneBio (NASDAQ:IMA) with a Underperform rating and announ
ImageneBio, Inc. (Nasdaq: IMA, "Imagene," or the "Company"), a clinical-stage biotec
ImageneBio (NASDAQ:IMA) reported quarterly losses of $(2.91) per share which missed the analyst cons
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protoco
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” “Company”), a
ImageneBio, Inc. (NASDAQ: IMA - Get Free Report) was the recipient of a large growth in short intere
The consensus price target hints at a 695.5% upside potential for IMAGENEBIO INC (IMA). While empiri
SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“ImageneBio”), a clinic
The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”
Combined Company to Trade on Nasdaq Under Ticker “IMA” Ikena Announces 1-for-12 Reverse Stock Split
BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”